- Home
- VIVS vs SVRE Comparison
VIVS vs SVRE Comparison
Compare VIVS & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIVS | SVRE |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | Israel |
| Employees | 9 | 35 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VIVS | SVRE |
|---|---|---|
| Price | $1.31 | $5.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.8K | 39.8K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | $1,793.31 |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.55 |
| 52 Week High | $5.30 | $6.30 |
Technical Indicators
Market Signals| Indicator | VIVS | SVRE |
|---|---|---|
| Relative Strength Index (RSI) | 33.71 | 56.47 |
| Support Level | $1.25 | $1.03 |
| Resistance Level | $1.88 | $6.30 |
| Average True Range (ATR) | 0.08 | 0.53 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 9.41 | 46.52 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.